Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Last trade$0.3192
Day change-$0.0144 (-4.32%)
Day range$0.313 – $0.341
Volume5,014,901
Market cap$76M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$75.22M
Price / earnings
—
Price / book
1.38×
Price / sales
24.81×
EV / sales
2.78×
EV / EBITDA
-0.11×
Profitability
Earnings per share
-$0.45
Return on assets
-132.73%
Return on equity
-186.69%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.78×
Quick ratio
3.78×
Cash ratio
3.55×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$54.65M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TNYA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.7M
$1.11M
$225K
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.7M
$1.11M
$225K
$0
$0
$0
$0
$0
Selling, general and administrative
$5.65M
$5.41M
$5.45M
$5.98M
$5.57M
$6.71M
$6.46M
$5.96M
Research and development
$14.87M
$16.6M
$14.84M
$14.8M
$15.36M
$17.37M
$21.08M
$18.69M
Total operating expenses
$21.18M
$43.83M
$20.29M
$20.78M
$20.94M
$24.08M
$27.54M
$24.65M
Operating income
-$19.48M
-$42.72M
-$20.07M
-$20.78M
-$20.94M
-$24.08M
-$27.54M
-$24.65M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$18.94M
-$43.39M
-$19.27M
-$20.18M
-$20.28M
-$23.28M
-$26.86M
-$23.84M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$18.94M
-$43.39M
-$19.27M
-$20.18M
-$20.28M
-$23.28M
-$26.86M
-$23.84M
Net income attributable to common shareholders
-$18.94M
-$43.39M
-$19.27M
-$20.18M
-$20.28M
-$23.28M
-$26.86M
-$23.84M
EBITDA
-$18.42M
-$19.2M
-$18.3M
-$18.95M
-$19.07M
-$22M
-$24.88M
-$22.56M
Basic earnings per share
-$0.08
-$0.20
-$0.09
-$0.11
-$0.12
-$0.14
-$0.24
-$0.28
Diluted earnings per share
-$0.08
-$0.20
-$0.09
-$0.11
-$0.12
-$0.14
-$0.24
-$0.28
Recent news
Company coverage with links to the original publishers.
Tenaya Therapeutics shares surged 31.20% following a research collaboration agreement with Alnylam Pharmaceuticals focused on discovering genetic targets for cardiovascular disease treatments. Tenaya will validate up to 15 gene targets and receive up to $10 million in upfront payments with potential milestone payments reaching $1.13 billion. Despite the positive news, the stock remains in a bearish trend trading below its 100-day and 200-day moving averages.
Tenaya Therapeutics shared interim data from its MyClimb study on pediatric patients with MYBPC3-associated hypertrophic cardiomyopathy, revealing significant risks and disease progression patterns across different genetic inheritance groups.
The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.